Eloxx Pharmaceuticals (ELOX) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $56.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | INKT |
|---|---|---|
| Share price | $15.18 | $11.00 |
| Market cap | $61.27M | $56.13M |
| 1-day change | +2.02% | -3.68% |
| YTD return | — | -1.35% |
| 1-year return | — | -24.61% |
| 5-year return | — | -90.83% |
| P/E ratio (TTM) | 4.31 | — |
| EPS (TTM) | $3.52 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $16.93 |
| 52-week low | $8.20 | $8.48 |
| Distance from 52-week high | -35.13% | -35.02% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +151.98% | +254.55% |
| Average volume | 46.44K | 13.80K |
| Shares outstanding | 4.04M | 5.10M |
| Employees | 10 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Healthcare · Biotechnology · 10 employees
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Healthcare · Biotechnology · 15 employees
ELOX vs INKT FAQ
Which is bigger, Eloxx Pharmaceuticals or MiNK Therapeutics?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $56.13M for MiNK Therapeutics (INKT).
Are Eloxx Pharmaceuticals and MiNK Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.